Multicenter Real-World Data of Subsequent Chemotherapy after Progression to PARP Inhibitors in a Maintenance Relapse Setting

SIMPLE SUMMARY: Since the irruption of PARPi in the therapeutic armamentarium for ovarian cancer, concerns regarding post-progression treatment outcomes have emerged, owing to known crossed-resistance mechanisms between PARPi and platinum. In this multicentric retrospective series of ovarian cancer...

Descripción completa

Detalles Bibliográficos
Autores principales: Romeo, Margarita, Gil-Martín, Marta, Gaba, Lydia, Teruel, Iris, Taus, Álvaro, Fina, Claudia, Masvidal, Maria, Murata, Paola, Fernández-Plana, Julen, Martínez, Alejandro, Pérez, Cristina, García, Yolanda, Rodriguez, Valerie, Cros, Sara, Parera, Marta, Zanui, Montserrat, Catot, Silvia, Pardo, Beatriz, Plaja, Andrea, Esteve, Anna, Barretina-Ginesta, Maria Pilar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9497128/
https://www.ncbi.nlm.nih.gov/pubmed/36139574
http://dx.doi.org/10.3390/cancers14184414

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9497128/
https://www.ncbi.nlm.nih.gov/pubmed/36139574
http://dx.doi.org/10.3390/cancers14184414

Ejemplares similares